liveBook · Manning

Druggability

As explained in Build AI Drug Discovery Pipelines

A druggability assessment evaluates whether a biological target has features that make it amenable to modulation by a drug-like molecule.

Druggability assessment asks whether a biological target contains features suitable for modulation by a drug-like molecule. For TNIK in idiopathic pulmonary fibrosis, the assessment predicted that its kinase domain could support small-molecule inhibition: the ATP-binding pocket offered a defined site, while sequence differences from other kinases suggested a path toward selectivity. section 13.3.1

TNIK as a target

TNIK combined substantial biological evidence with limited prior investigation: it participated in inflammatory and fibrotic signaling, genetic studies linked its locus to fibrotic disease, and IPF tissue showed increased expression. After analysis and expert review, it was selected despite lacking selective inhibitors or ligand-bound crystal structures. section 13.3.1

How Build AI Drug Discovery Pipelines covers it

How deep it goes
Assesses domain suitability and pocket differentiation, but does not detail a computational scoring algorithm.
Examples
Uses TNIK in idiopathic pulmonary fibrosis as an example, including its kinase domain and absent prior selective inhibitors.
What you can do after
Evaluate whether a target offers a plausible and selective starting point for small-molecule drug discovery.
How it connects
Connects target selection with kinase inhibition, ATP-binding pockets, sequence analysis, and off-target risk.

This explainer was generated by Manning's knowledge graph from the text of Build AI Drug Discovery Pipelines. The section links point to the parts of the book it draws on.